Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emil F Pai

Showing results (41-50 of 103) with videos related to

Pageof 11
Sort By:
Journal of Molecular Biology|August 12, 2008
Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6Steve Bryson, Jean-Philippe Julien, David E Isenman, et al.
The Journal of Biological Chemistry|August 25, 2023
Allopurinol and oxypurinol differ in their strength and mechanisms of inhibition of xanthine oxidoreductaseMai Sekine, Ken Okamoto, Emil F Pai, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 21, 2003
Unique amino acids cluster for switching from the dehydrogenase to oxidase form of xanthine oxidoreductaseYoshimitsu Kuwabara, Tomoko Nishino, Ken Okamoto, et al.
The FEBS Journal|March 31, 2015
The C-terminal peptide plays a role in the formation of an intermediate form during the transition between xanthine dehydrogenase and xanthine oxidaseTomoko Nishino, Ken Okamoto, Yuko Kawaguchi, et al.
The EMBO Journal|September 6, 2008
Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirusChristy A Thomson, Steve Bryson, Gary R McLean, et al.
Journal of the American Chemical Society|October 27, 2005
An unprecedented twist to ODCase catalytic activityMasahiro Fujihashi, Angelica M Bello, Ewa Poduch, et al.
The Journal of Biological Chemistry|May 10, 2005
Mechanism of the conversion of xanthine dehydrogenase to xanthine oxidase: identification of the two cysteine disulfide bonds and crystal structure of a non-convertible rat liver xanthine dehydrogenase mutantTomoko Nishino, Ken Okamoto, Yuko Kawaguchi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 17, 2016
Structures of Preferred Human IgV Genes-Based Protective Antibodies Identify How Conserved Residues Contact Diverse Antigens and Assign Source of Specificity to CDR3 Loop VariationSteve Bryson, Christy A Thomson, Louise F Risnes, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|August 14, 2019
Targeting a Large Active Site: Structure-Based Design of Nanomolar Inhibitors of Trypanosoma brucei Trypanothione ReductaseRaoul De Gasparo, Ondrej Halgas, Dora Harangozo, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 11, 2004
Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretionAtsushi Fukunari, Ken Okamoto, Takeshi Nishino, et al.
Pageof 11

Showing results (41-50 of 103) with videos related to

Sort By:
Pageof 11
Journal of Molecular Biology|August 12, 2008
Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6Steve Bryson, Jean-Philippe Julien, David E Isenman, et al.
The Journal of Biological Chemistry|August 25, 2023
Allopurinol and oxypurinol differ in their strength and mechanisms of inhibition of xanthine oxidoreductaseMai Sekine, Ken Okamoto, Emil F Pai, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 21, 2003
Unique amino acids cluster for switching from the dehydrogenase to oxidase form of xanthine oxidoreductaseYoshimitsu Kuwabara, Tomoko Nishino, Ken Okamoto, et al.
The FEBS Journal|March 31, 2015
The C-terminal peptide plays a role in the formation of an intermediate form during the transition between xanthine dehydrogenase and xanthine oxidaseTomoko Nishino, Ken Okamoto, Yuko Kawaguchi, et al.
The EMBO Journal|September 6, 2008
Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirusChristy A Thomson, Steve Bryson, Gary R McLean, et al.
Journal of the American Chemical Society|October 27, 2005
An unprecedented twist to ODCase catalytic activityMasahiro Fujihashi, Angelica M Bello, Ewa Poduch, et al.
The Journal of Biological Chemistry|May 10, 2005
Mechanism of the conversion of xanthine dehydrogenase to xanthine oxidase: identification of the two cysteine disulfide bonds and crystal structure of a non-convertible rat liver xanthine dehydrogenase mutantTomoko Nishino, Ken Okamoto, Yuko Kawaguchi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 17, 2016
Structures of Preferred Human IgV Genes-Based Protective Antibodies Identify How Conserved Residues Contact Diverse Antigens and Assign Source of Specificity to CDR3 Loop VariationSteve Bryson, Christy A Thomson, Louise F Risnes, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|August 14, 2019
Targeting a Large Active Site: Structure-Based Design of Nanomolar Inhibitors of Trypanosoma brucei Trypanothione ReductaseRaoul De Gasparo, Ondrej Halgas, Dora Harangozo, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 11, 2004
Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretionAtsushi Fukunari, Ken Okamoto, Takeshi Nishino, et al.
Pageof 11